Fouad K. Habib  European Urology Supplements 

Slides:



Advertisements
Similar presentations
The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) 
Advertisements

Medical Management for BPH: The Role of Combination Therapy
Pascal Rischmann  European Urology Supplements 
Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management  Michael O’Leary  European Urology Supplements 
Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer  Marisa Warmuth,
Treatment Strategies in Advanced Prostate Cancer/Genitourinary Malignancies: The Use of Bisphosphonates Across the Continuum  John M. Fitzpatrick, Marc.
Management of Acute and Chronic Retention in Men
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Prostate Cancer Epidemic in Sight?
Treatment of Advanced and Metastatic Renal Cancer: A Revolution?
Back to the Future: Introduction and Conclusions
Alexandre de la Taille  European Urology Supplements 
Pseudohyperplastic Adenocarcinoma of the Prostate
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening?  Bob Djavan  European.
Counselling the Prostate Cancer Patient
Laurent Boccon-Gibod  European Urology Supplements 
Prostate Cancer Epidemic in Sight?
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
An Update of Current Practice in Hypospadias Surgery
Richard C. Harkaway  European Urology Supplements 
Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection
Tim Schneider  European Urology Supplements 
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Transurethral Resection of the Prostate
Fouad K. Habib  European Urology Supplements 
Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):
The Importance of Testosterone Control in Prostate Cancer
Jacques Irani  European Urology Supplements 
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Neal Shore  European Urology Supplements 
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Sergio Bracarda  European Urology Supplements 
Jean J.M.C.H. de la Rosette, Vladimir Mouraviev, Thomas J. Polascik 
Pharmacotherapy in Stress and Mixed Incontinence
What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice?  François Desgrandchamps  European Urology.
Christian Stief  European Urology Supplements 
Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma  Fred Saad  European Urology.
New Trends in Managing the Prostate Cancer Patient
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Ureteropelvic Junction Obstruction
Preclinical Profile of Zoledronic Acid in Prostate Cancer Models
Emmanuel Chartier-Kastler, Kate Davidson  European Urology Supplements 
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Who Forms Stones and Why?
Martin Michel, Jean de la Rosette  European Urology Supplements 
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
The European Online Sexual Survey (EOSS): Pan-European Perspectives on the Impact of Premature Ejaculation and Treatment-Seeking Behavior  John Dean 
Improving Flexibility and Quality of Life for Your Patients: A Must?
Profile of Silodosin European Urology Supplements
Volume 143, Issue 6, (December 2010)
Androgen Receptor Mediated Growth of Prostate (Cancer)
Complex Mechanisms in Prostatic Inflammatory Response
Epidemiology, Pathogenesis, and Pathophysiology of Urolithiasis
The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) 
The Benefits of Dual Inhibition of 5α Reductase
C.G Roehrborn, T McNicholas  European Urology Supplements 
Treatment Options in Prostate Cancer Once Primary Therapy Fails
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Joaquim Bellmunt  European Urology Supplements 
The Impact of Premature Ejaculation on Partners and Relationships
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice 
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Epidemiology and Demographics of Prostatitis
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Jan Roigas  European Urology Supplements 
Michael Marberger  European Urology Supplements 
Introduction European Urology Supplements
Presentation transcript:

Serenoa repens: The Scientific Basis for the Treatment of Benign Prostatic Hyperplasia  Fouad K. Habib  European Urology Supplements  Volume 8, Issue 13, Pages 887-893 (December 2009) DOI: 10.1016/j.eursup.2009.11.005 Copyright © 2009 Terms and Conditions

Fig. 1 (a) Electron micrographs of untreated cocultured fibroblast cells. Micrograph A (×3888) shows characteristic elongated nuclei (N), high levels of Golgi apparatus (G), and cilia. Micrograph B (×86 400) shows a collagen fibril (F) produced by the cocultured fibroblast cells. (b) Electron micrographs of Serenoa repens extract (SrE)–treated (10μg/ml) cocultured fibroblast cells. Micrograph A (×15 984) shows general disruption of the cell cytoplasm and accumulation of lipids (L) in the cell. Micrograph B shows damage to the Golgi apparatus (G) in a fibroblast cell treated with SrE [5]. European Urology Supplements 2009 8, 887-893DOI: (10.1016/j.eursup.2009.11.005) Copyright © 2009 Terms and Conditions

Fig. 2 Effect of a 5-d treatment with Serenoa repens extract (SrE) (10μg/ml) on the activity of 5α-reductase types I (5α-R1) and II (5α-R2) in cocultured epithelial and fibroblast cells. Each data set is the result of three separate experiments. Results are expressed as means plus or minus standard error of the mean [5]. DHT=dihydrotestosterone. European Urology Supplements 2009 8, 887-893DOI: (10.1016/j.eursup.2009.11.005) Copyright © 2009 Terms and Conditions

Fig. 3 Effect of a 2-d treatment with Serenoa repens extract (10μg/ml) on the activity of 5α-reductase types I and II in primary cultured cells from prostate, skin, breast, epididymis, testes, and kidney [13]. European Urology Supplements 2009 8, 887-893DOI: (10.1016/j.eursup.2009.11.005) Copyright © 2009 Terms and Conditions

Fig. 4 Visual representation of the content of 14 brands of SrE, as determined by analysis [3]. FFA=free fatty acids. European Urology Supplements 2009 8, 887-893DOI: (10.1016/j.eursup.2009.11.005) Copyright © 2009 Terms and Conditions

Fig. 5 Schematic diagram showing some of the Serenoa repens extract (SrE) targets at the level of the prostate cell. DHT=dihydrotestosterone; EGF=epidermal growth factor; FGF=fibroblast growth factor. European Urology Supplements 2009 8, 887-893DOI: (10.1016/j.eursup.2009.11.005) Copyright © 2009 Terms and Conditions